Study: Mobile retail to grow as much as 68% in 2016
NEW YORK — Mobile purchasing looks set for major growth in 2016.
According to new projections from Bizrate Insights, a division of Connextiy, based on month-over-month order volume in November 2015, mobile website purchases will increase by as much as 68% from 2015 to 2016. The peak volume during the 2016 holiday season may reach as high as 42%, nearly half of all online orders.
This does not include in-app purchases, meaning total mobile purchases will almost certainly total a higher percentage of all online orders in 2016. When broken out between smartphone and tablet, Bizrate Insights’ 2016 projections show a clear majority of website purchases going to phones, which represented 33% of all online orders in November.
Meanwhile, in the absence of meaningful innovation, tablet purchases are expected to stagnate, if not decline slightly. However, retailers should not discount tablets as an e-commerce platform entirely. Although smartphones have overtaken tablets in mobile website purchases since the early summer of 2015, orders placed by iPads still surpassed individual iPhone and Android phone volume through the year.
Dr. Reddy’s relaunches its generic Nexium
HYDERABAD, India — Dr. Reddy's on Wednesday announced that it has relaunched its esomeprazole magnesium delayed-release capsues, the generic version of AstraZeneca's Nexium delayed-release capsules, in the United States.
The relaunch is due to a change in the capsue color.
Dr. Reddy's originally launched the drug in September 2015 for the treatment of gastroesophageal reflux disease, stomach ulcers and a damaged esophagus.
Mylan launches generic Zyvox
PITTSBURGH — Mylan on Tuesday announced it is launching linezolid tablets, the generic version of Pfizer's Zyvox.
Mylan received Food and Drug Administration approval to launch linezolid tablets in the 600 mg strength to treat certain infections caused by susceptible Gram-positive bacteria in adults and children.
Linezolid tablets, 600 mg, had U.S. sales of approximately $457.8 million for the 12 months ended Sept. 30, according to IMS Health.